J&J Expects Innovative Medicines Growth Despite Stelara LOE: Here's Why

Johnson & Johnson (JNJ) reported a 42.7% sales decline for its key immunology drug Stelara in Q2 2025 following patent expiry and biosimilar entry, which negatively impacted its Innovative Medicine segment by 1170 basis points. Despite this significant headwind, J&J projects its Innovative Medicine sales to remain largely flat at over $57 billion in 2025 compared to 2024. This resilience is fueled by robust double-digit growth from established products like Darzalex, Tremfya, Spravato, and Erleada, alongside new oncology drugs such as Carvykti, Tecvayli, and Talvey, effectively mitigating the impact of Stelara's loss of exclusivity.

Analysis

Johnson & Johnson is demonstrating resilience in the face of a significant patent cliff for its blockbuster drug, Stelara. The loss of exclusivity (LOE) has had a material impact, evidenced by a 42.7% year-over-year decline in Stelara's Q2 2025 sales and a negative 1170 basis point drag on the Innovative Medicine segment's growth. Despite this headwind, which is projected to erode Stelara's annual sales from nearly $11 billion in 2023 to around $2.7 billion by 2027, J&J's management has guided for segment sales to remain stable at over $57 billion in 2025, roughly flat with 2024. This stability is underpinned by strong, double-digit growth from key products like Darzalex, Tremfya, Spravato, and Erleada. Furthermore, the company is successfully commercializing new assets, with its three new cancer drugs contributing $1.3 billion in the first half of 2025 and Tremfya's expansion into IBD indications positioning it as a potential $10 billion product. The market has reacted positively to this effective portfolio management, with JNJ's stock outperforming the industry by 22.6% year-to-date, though it now trades at a slight valuation premium with a forward P/E of 15.78, above the industry average of 14.78. The marginal upward revisions in 2025 and 2026 earnings estimates suggest analysts are confident in this growth-offset strategy.

Key Decisions for Investors

• Investors should recognize that the market is currently pricing in J&J's ability to successfully navigate the Stelara patent cliff, focusing on the strength of its diversified growth drivers over the significant revenue loss.
• It is critical to monitor the quarterly sales performance of the key growth portfolio, particularly Darzalex, Tremfya, and the new oncology drugs, as their sustained double-digit growth is essential to neutralize the Stelara headwind and justify the company's guidance.
• Given the stock's 22.6% year-to-date outperformance and its valuation at a slight premium to both the industry and its five-year average, investors should be mindful that much of the successful LOE transition may already be reflected in the current share price.
• Consider the competitive dynamics, as a faster-than-expected market penetration by Stelara biosimilars from competitors like Amgen and Teva could accelerate sales erosion and challenge J&J's ability to maintain its flat revenue guidance for the Innovative Medicines segment.